SpainSpain

US pressure on GM-critics?

06.02.2011

Madrid – Nowhere in the world, is the concentration of GM-sceptics higher than it is in Europe, but their reign is not supreme. On the south-western tip of the continent, Spain stands out for its “science-based agricultural biotechnology position”. That’s not really news. What makes the evaluation noteworthy though, is that it is comes from a US diplomatic cable published by the website Wikileaks. In recent weeks, several such cables have emerged revealing that under the Bush administration, American diplomats were not shy about using all their influence to fight against a further tightening of GM laws in Europe. Relations between the US administration and commercial GM crop producers appear to have been cordial. The British daily the Guardian cited a cable that: “In response to recent urgent requests by [Spanish rural affairs ministry] state secretary Josep Puxeu and Monsanto,” the American embassy in Madrid was urging “renewed US government support of Spain’s science-based agricultural biotechnology position through high-level US government intervention.” Other cables suggest that Spain and the US have worked closely together to persuade the EU not to further tighten biotechnology laws. In another message cited by the Guardian, the US Ambassador to France recommended the US “calibrate a target list that causes some pain across the EU” because both government and citizens were for the most part opposed to GM crops.
Spanish maize farmers, however, don’t seem much impressed by the Wikileaks revelations. According to a recent survey commissioned by the GMO-friendly Antama Foundation, most of them don’t use transgensic seeds because they don’t have problems with the European corn borer. Most are indifferent (61%) or in favour (18%) of planting GM maize. A large majority (93%) of the farmers who planted Bt-maize in 2010 said they will do so again this year. The study involved 200 farmers in Catalonia and Aragon. One fifth of Spain’s 400,000 hectares of maize acreage are currently planted with GM maize.

SpainSpain

01.10.2011

Granada – Alentia Biotech, a joint venture of Grupo Ferrer Internacional S.A. and Laboratorios Farmacéuticos Rovi S.A, has announced plans to construct a national production centre to supply the Spanish population with flu...

SpainSpain

01.10.2011

Lisbon – A Portuguese-American research team has discovered an association between a variant in the gene DZIP1 and Parkinson’s disease (PD). The collaboration brought André Valente from the Biocant Biotechnology Innovation Center...

SpainSpain

29.09.2011

Granada - Alentia Biotech, a joint venture of Spanish pharmaceuticals companies Laboratorios Farmaceuticos Rovi SA and Ferrer, will invest €92m in the construction of a flu vaccines plant in Granada. The annual production...

SpainSpain

23.09.2011

Madrid - Spain unveiled a grand alliance between all stakeholders in biomedicine to foster innovation in the sector. Minister of Science and Innovation, Cristina Garmendia, met the representatives of institutions, public research...

Italy, SpainSpain

18.08.2011

Vinaros – The Italian company Transactiva failed to start a field trial of a genetically modified rice variant in southeastern Spain. Although the National Commission on Biosafety had approved the field trial, the Committee on...

SpainSpain

09.08.2011

Madrid/Ingelheim – Pharmaceutical company Boehringer Ingelheim has cleared the way for Spanish rival Almirall and ended a long-standing patent squabble, although the reconciliation was not exactly voluntary. Behind the scenes,...

SpainSpain

13.06.2011

Madrid – Spain is working to establish itself as a European hotspot for bio­energy production. The country’s Abengoa Bioenergia Nuevas Tecnologias, a subsidiary of Abengoa Bioenergy, will lead an international consortium in the...

SpainSpain

11.06.2011

Madrid – Agendas, working committees and associations in Europe’s biotechnology sector are not hard to find. Now the spanking new Spanish Biotech Platform (launched in May) has to show if it is more than just another extension of...

SpainSpain

06.02.2011

Madrid – Noscira, a Madrid-based company looking for Alzheimer treatments in marine life forms, raised a19m in a private placement of 3.8 million shares at EUR5 to existing and new investors. The main stakeholder is Zeltia S.A,...

Displaying results 11 to 20 out of 181

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-spain/browse/1/article/us-pressure-on-gm-critics.html

Product of the week

Products

Events

All Events

Current issue

All issues